More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contr

Posted 3 months ago in Short Stories.

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.

 

To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

The USD 1.7 billion financial opportunity (by 2030) within the ophthalmic drugs contract manufacturing market has been analyzed across the following segments:

  • Type of product
  • Ophthalmic API
  • Ophthalmic drug FDF

 

  • Type of FDF manufactured
  • Solid
  • Semi-solid
  • Liquid / suspension

 

  • Type of primary packaging
  • Ampoule / vial
  • Glass / plastic bottle
  • Ointment tube
  • Blister packing
  • Other forms

 

  • Scale of manufacturing
  • Clinical
  • Commercial

 

  • Company size
  • Small
  • Mid-sized
  • Large
  • Very large

 

  • Target disease indication
  • Age-related macular degeneration
  • Dry eye
  • Glaucoma
  • Other disease segments

 

  • Key geographical regions
  • North America (US, Canada and Mexico)
  • Europe (UK, Germany, France, Spain, Italy and rest of Europe)
  • Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
  • Rest of the world

 

The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” report features the following companies, which we identified to be key players in this domain:

  • Akorn
  • Akums
  • Bal Pharma
  • Catalent
  • Cayman Chemical
  • Entod Pharmaceuticals
  • Farmigea
  • Glenmark Pharmaceuticals
  • Indiana Ophthalmics
  • Lomapharm
  • Medichem
  • Pillar5 Pharma
  • Recipharm
  • Salvat
  • Sterling Pharmaceutical Services
  • Sunways India

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Current Market Landscape
  4. Company Competitiveness Analysis
  5. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles
  6. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles
  7. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles
  8. Clinical Trial Analysis
  9. Capacity Analysis
  10. Demand Analysis
  11. Market Forecast
  12. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies
  13. SWOT Analysis

 

  1. Survey Analysis

 

  1. Executive Insights

 

  1. Future Growth Opportunities

 

  1. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers

 

  1. Appendix 2: Tabulated Data

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Living in Afghanistan